Abstract
Epilepsy is a chronic neurological disorder characterized by recurrent seizures and associated neurological, cognitive, psychological, and social effects. The prevalence of active epilepsy is estimated to be between 4-10 per 1000 individuals in the general population, with the highest incidence occurring during infancy and childhood. Genetic mutations play a significant role in epilepsy, and over 500 genes have been associated with the condition. Next-Generation Sequencing (NGS) panels are utilized for genetic testing, but a substantial proportion of results remain uncertain and are not considered directly causative of epilepsy. In this study, we reevaluated a subgroup of patients with inconclusive variant findings or multiple Variants of Uncertain Significance (VUSs) in their test results. We identified two unrelated variants c.2133G>C in SCN9A and c.316G>A in QARS1 to be potentially pathogenic variants. Additionally, we identified a frequent genetic combination, the RANBP2&RYR3 being prominent among other possible combinations. The RANBP2 gene consistently co-occurred with RYR3 variants in uncertain results, suggesting potential pathogenicity. We also analyzed unaffected parents’ data and observed certain combinations inherited from different parents, raising the possibility of specific gene combinations as risk factors for the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Zuckerman STEM Leadership Program and Israel science foundation (ISF) grants 1994/21 and 352/21.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of The Sheba Fund for Health Services and Research gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
